Physician profile
John Ryan Torres
NPI 1467074054
$416.80
in general payments reported to CMS, 2019-2025
11 companies · $40.06 in 2025
The $40.06 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $144 · 2022: $27.02 · 2023: $78.04 · 2024: $128 · 2025: $40.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $246.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $100.47 | 2021 | |
| Merck Sharp & Dohme LLC | $76.36 | 2023-2024 | Verquvo |
| Exact Sciences Corporation | $52.42 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $50.01 | 2021-2024 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $32.46 | 2022-2024 | Xarelto |
| Glaxosmithkline, LLC. | $28.27 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $18.53 | 2024 | |
| Daiichi Sankyo INC. | $17.00 | 2023 | Injectafer |
| Novartis Pharmaceuticals Corporation | $14.05 | 2024 | |
| Amgen INC. | $13.63 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.60 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ryan Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.